Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates.

Kim, Albert M; Somayaji, Veena R; Dong, Jennifer Q; Rolph, Timothy P; Weng, Yan; Chabot, Jeffrey R; Gropp, Kathryn E; Talukdar, Saswata; Calle, Roberto A

Kim, Albert M; Somayaji, Veena R; Dong, Jennifer Q; Rolph, Timothy P; Weng, Yan; Chabot, Jeffrey R; Gropp, Kathryn E; Talukdar, Saswata; Calle, Roberto A.

Affiliation

Kim AM; Pfizer Inc., Cambridge, Massachusetts, USA.
Somayaji VR; Pfizer Inc., Cambridge, Massachusetts, USA.
Dong JQ; Pfizer Inc., Cambridge, Massachusetts, USA.
Rolph TP; Pfizer Inc., Cambridge, Massachusetts, USA.
Weng Y; Pfizer Inc., Cambridge, Massachusetts, USA.
Chabot JR; Pfizer Inc., Cambridge, Massachusetts, USA.
Gropp KE; Pfizer Inc., Groton, Connecticut, USA.
Talukdar S; Pfizer Inc., Cambridge, Massachusetts, USA.
Calle RA; Pfizer Inc., Cambridge, Massachusetts, USA.

Diabetes Obes Metab ; 19(12): 1762-1772, 2017 12.

Article in En | MEDLINE | ID: mdl-28573777

Subject(s)

Anti-Obesity Agents/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Bone Remodeling/drug effects; Fibroblast Growth Factors/therapeutic use; Hypertriglyceridemia/drug therapy; Hypolipidemic Agents/therapeutic use; Obesity/drug therapy; Animals; Anti-Obesity Agents/administration & dosage; Anti-Obesity Agents/adverse effects; Anti-Obesity Agents/pharmacokinetics; Antibodies, Monoclonal, Humanized/administration & dosage; Antibodies, Monoclonal, Humanized/adverse effects; Antibodies, Monoclonal, Humanized/pharmacokinetics; Biomarkers/blood; Body Mass Index; Delayed-Action Preparations/administration & dosage; Delayed-Action Preparations/adverse effects; Delayed-Action Preparations/pharmacokinetics; Delayed-Action Preparations/therapeutic use; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Female; Fibroblast Growth Factors/administration & dosage; Fibroblast Growth Factors/adverse effects; Fibroblast Growth Factors/pharmacokinetics; Follow-Up Studies; Half-Life; Humans; Hypertension/chemically induced; Hypertension/physiopathology; Hypertriglyceridemia/blood; Hypertriglyceridemia/complications; Hypolipidemic Agents/administration & dosage; Hypolipidemic Agents/adverse effects; Hypolipidemic Agents/pharmacokinetics; Infusions, Intravenous; Male; Middle Aged; Obesity/blood; Obesity/complications; Severity of Illness Index; Species Specificity

Key words

IGF-1; blood pressure; bone biomarkers; fibroblast growth factor 21; heart rate; type 2 diabetes

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hypertriglyceridemia / Bone Remodeling / Anti-Obesity Agents / Antibodies, Monoclonal, Humanized / Fibroblast Growth Factors / Hypolipidemic Agents / Obesity Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2017 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google